Chemist Warehouse, RD Saúde, Dis-Chem and GoodRx found margin past the counter. Rite Aid and Medly ran out of suppliers willing to fill their shelves.
Pharmacy Case Study Examples
Case 1
Here are six pharmacy businesses, and each pharmacy case study below shows where the money really came from. Four turned buying power, store density and price data into lasting revenue, and two lost the ability to keep their shelves stocked.
A pharmacy looks like a protected business: licensed staff, regulated products and customers who come back every month for the same prescription. The economics are tighter than that. Dispensing margins are thin, the stock on the shelves is paid for before it is sold, and wholesalers ship on credit only while they trust the buyer. The four successes found four different answers to the margin problem: one turned its shopper traffic into a marketing business, one used its stores as a delivery network, one turned independent rivals into franchisees and one sold patients the price they could not see. Both failures lost the same thing in the end, which was a supplier willing to fill the shelves. In every one of the six, the outcome turned on where the margin really came from and on who paid for the inventory when a bad month arrived.
Case Study 1: Chemist Warehouse, the Discount Pharmacy Business Model That Sells Its Traffic
Two brothers bought a pharmacy in Reservoir, a suburb of Melbourne, in 1972, and a third pharmacist joined them in 1980. In February 2025 the business they built was merged into the listed wholesaler Sigma Healthcare, with its own shareholders taking 85.75% of the combined group. In the year to June 2025 its retail network sold A$10.3 billion to customers.
About the Business
Type: Discount retail pharmacy franchisor with its own wholesale and distribution arm
Founded/Launched: 1972, Reservoir, Melbourne, by Jack and Sam Gance; Mario Verrocchi joined in 1980
Revolution: Built Australia's largest discount pharmacy chain, with the brand acting as a buying and marketing service for pharmacist franchisees.
There are more than 5,900 pharmacies in Australia. A single community pharmacy buys in small quantities, has little to offer a supplier in a negotiation and pays for advertising that only one shop can use. Competing on price from that position means giving up the margin that keeps the shop open.
Buying power as the product: The company attributes its everyday low prices to strong buying power, and its central service business built particular strengths in marketing, pharmacy support and negotiating terms with suppliers.
Franchise the pharmacist, keep the system: Arrangements with member pharmacies were formalised under a franchise model from 2016, and every Chemist Warehouse and My Chemist pharmacy in Australia is franchised. Franchisees get marketing, training, and sales and inventory systems from the centre.
Marketing as a revenue line: In the 2023 financial year, marketing, advertising, promotional and other income made up about 20% of the group's revenue, ten times the share from franchise and related fees; about 73% came from sales of goods, including wholesale through its distribution centres. The group also runs media, advertising and marketing services.
The Results
Financial Metric/Exit: The merger was announced in December 2023 with an indicative market capitalisation above A$8.8 billion; the founders were to hold about 49% of the merged group. In the half to December 2025 the group reported normalised net profit after tax of A$392.0 million, up 19.2%.
Scale/Impact: 550 Chemist Warehouse branded stores in Australia, whose sales rose 17.2% to A$5.1 billion in the half, plus 70 stores in New Zealand and 17 in Ireland.
Revolutionary Insight: In a discount pharmacy, the profit is in the traffic, not the price tag.
Low prices bring the customers, and the traffic itself becomes something to sell: a fifth of revenue came from marketing, advertising and promotion rather than from goods. The franchise structure keeps a pharmacist behind each counter while the centre does the buying, the advertising and the logistics, which is the part that grows with scale.
Case 2
Case Study 2: RD Saúde, the Omnichannel Pharmacy Model That Turned Its Stores Into a One-Hour Warehouse
RD Saúde was formed in 2011 when Drogasil and Raia, two Brazilian pharmacy brands each about a century old, merged. In 2025 it served 51.7 million customers from 3,547 pharmacies and booked BRL 11.3 billion through digital channels, with 97% of those orders picked up or delivered in less than an hour.
About the Business
Type: Pharmacy chain with digital channels, in-store health services and its own distribution network
Founded/Launched: 2011, through the merger of Raia and Drogasil; run from the RD Saúde Campus in São Paulo and listed on the B3 exchange
Revolution: Used the pharmacy network itself as the fulfilment system for online orders.
A pharmacy chain in a country the size of Brazil faces two threats at once. Online sellers can ship from a central warehouse without paying for hundreds of shopfronts, and towns far from the big cities are expensive to reach. Many patients still depend on the nearest counter: the company notes that millions of Brazilians rely on pharmacies as a primary source of care, especially people living with chronic conditions.
Open stores at a steady pace: The company opened 330 new pharmacies in 2025 and now operates in 663 municipalities across every state, supplied by 15 distribution centres and a logistics hub.
Digital orders filled from the nearest store: Revenue from digital channels rose 59.3% to BRL 11.3 billion, and nearly every order was ready within the hour.
The pharmacy as a clinic: 2,800 pharmacies have Espaço Mais Saúde service rooms and 426 have vaccination rooms; teams of qualified staff, including 14,360 pharmacists, delivered about 7 million healthcare services in the year.
The Results
Financial Metric/Exit: Gross revenue of BRL 47,609.6 million in 2025, up 13.9% from BRL 41,782.0 million; adjusted net income of BRL 1,343.5 million and adjusted EBITDA of BRL 3.4 billion, at a 7.1% margin.
Scale/Impact: An 18.0% national market share by IQVIA's ex-factory measure, up 1.5 percentage points in a year.
Revolutionary Insight: A pharmacy chain can beat online sellers on time rather than on price.
A central warehouse ships tomorrow; a store a few streets away delivers within the hour. RD Saúde did not build a separate e-commerce operation; it turned 3,547 counters into collection and dispatch points. The 7.1% margin, achieved in what the company calls a year of heavy investment in pricing, is a reminder that the network wins volume, not easy profit.
Case 3
Case Study 3: Dis-Chem, From a Discount Counter to an Independent Pharmacy Franchise for Rivals
Pharmacists Ivan and Lynette Saltzman founded Dis-Chem in 1978 and opened their first retail pharmacy in Mondeor, a southern suburb of Johannesburg. In the year to February 2026 the group reported revenue of R42.8 billion from 316 pharmacies, 42 baby stores and a franchise brand that now counts 280 independent pharmacies.
About the Business
Type: Pharmacy retailer with a wholesale arm and a franchise brand for independent pharmacies
Founded/Launched: 1978, Mondeor, Johannesburg; listed on the Johannesburg Stock Exchange in November 2016
Revolution: Brought the discount format to South African pharmacy, then offered independent pharmacists a franchise instead of trying to close them down.
Corporate groups hold between 65% and 70% of South Africa's pharmacy market. An independent pharmacist competes against chains with far larger buying power. A chain, in turn, eventually runs out of new sites, because the rest of the market belongs to owners who have no plan to sell.
Discount, with a wider shelf: The founders introduced the discount pharmacy and stocked product categories that had previously been unavailable in South African pharmacies because of restrictive legislation.
A franchise for independents: The wholesale arm supplies independent pharmacies, and its franchise brand, The Local Choice, grew from 240 to 280 franchisees in a year, with franchisee revenue up 16.4% to R2.9 billion. Management says the brand could reach 500 stores and as much as half of the independent market.
Loyalty and a health ecosystem: Management credits Better Rewards, its revamped loyalty and discount programme, with lifting foot traffic and market share, and new stores will follow a Health Hub format that combines pharmacy, clinics, digital care and insurance.
The Results
Financial Metric/Exit: Revenue up 9.3% to R42.8 billion and retail revenue up 9% to R36.6 billion. Basic headline earnings per share fell 17.3% to 113.7 cents, and the final dividend was cut by 42.8%.
Scale/Impact: 31 pharmacy outlets added in the year and 34 more planned for the 2027 financial year.
Revolutionary Insight: A franchise turns a competitor into a customer.
Every independent that joins The Local Choice buys through Dis-Chem's wholesale arm instead of a rival's, and Dis-Chem holds first right of refusal when a franchise is sold. The 2026 profit fall and the founding family's full exit from the board in July 2026 are the points to watch.
Case 4
Case Study 4: GoodRx, the Prescription Discount Business Model That Sells the Price Nobody Could See
GoodRx was formed in September 2011 and started with a price comparison tool for prescriptions. By its own count it has helped Americans save over $100 billion on medication since then, and in 2025 it earned $796.9 million of revenue and $30.4 million of net income.
About the Business
Type: Prescription price comparison and savings platform for U.S. retail pharmacies
Founded/Launched: September 2011; co-founded by Trevor Bezdek and Douglas Hirsch; initial public offering in September 2020
Revolution: Made the cash price of a prescription visible before the patient reached the counter.
The list price of the same medicine can vary significantly from one pharmacy to the next, and many consumers do not know it. Pharmacy benefit managers (PBMs) negotiate the prices with pharmacies and manufacturers, and a patient who finds the cost too high at the counter may simply walk away without the prescription.
Compare first: Consumers can choose the lowest price from a selection of nearby pharmacies, and can use GoodRx at nearly every retail pharmacy in the United States.
Free to the patient, paid by the PBM: When a consumer saves with a GoodRx code, the company receives a percentage of the saving or a fixed payment from the PBM whose pricing was used.
New lines beyond the discount code: Revenue from drug makers, now called Pharma Direct, rose 41% to $151.4 million in 2025; subscriptions brought in $83.8 million.
The Results
Financial Metric/Exit: Revenue up 1% to $796.9 million, net income of $30.4 million against $16.4 million, and adjusted EBITDA of $270.5 million.
Scale/Impact: Used by nearly 25 million consumers and over one million healthcare professionals a year.
Revolutionary Insight: Price transparency is a product people will use if someone else pays for it.
GoodRx charges the patient nothing and collects from the intermediaries whose prices it displays. The weakness is the same dependence: the company says a significant portion of its revenue comes from a limited number of PBMs, and prescription transactions revenue fell 6% in 2025, mainly because fewer consumers used its codes, which it linked to changes in retail pharmacy, including store closures. A platform built on pharmacies shrinks when pharmacies close.
Case 5
Case Study 5 (FAILED): Rite Aid, the Drugstore Chain Bankruptcy That Came Twice and Left an Empty Shelf
When Rite Aid filed for Chapter 11 on 15 October 2023, it was carrying more than $3 billion of long-term borrowings and ran more than 2,100 pharmacies across 17 states. It had served customers for more than 60 years. It emerged in September 2024 with about $2 billion less debt, filed again in May 2025 and by October 2025 had closed every store.
The Business
A U.S. drugstore chain based in Philadelphia, which had reported $24 billion in revenue and $750 million in losses before its first filing.
The Peak/Capital
More than 2,100 pharmacies in 17 states at the first filing, carrying $4 billion of funded debt; lenders committed $3.45 billion of new financing to fund the case.
The "Bitter Pill" Details
Debt that consumed the turnaround: Rite Aid paid about $200 million a year in interest and struggled to shed its $4 billion of funded debt, which limited its liquidity and its ability to carry out turnaround plans. A ratings agency had already cut it further into junk, citing debt maturing from 2025.
Stores that cost money after they closed: Its newly appointed chief executive described a "sub-optimal" retail footprint, and the company was paying $80 million a year in "dead rent" on closed stores whose leases it could not exit outside Chapter 11. During the first bankruptcy it closed all of its stores in Michigan and all but four in Ohio.
Lawsuits, then nervous suppliers: More than 1,600 opioid-related lawsuits were pending at the first filing, and trade contraction cost more than $100 million of liquidity in a few weeks. McKesson, its largest unsecured creditor, held trade claims of about $667.6 million. After the 2023 bankruptcy, vendors would ship only under strict terms, promised capital failed to materialise and the stores struggled against cheaper household essentials elsewhere.
The Financial Result
The first case cut about $2 billion of debt, raised about $2.5 billion of exit financing and left Rite Aid as a private company. At the second filing the chain ran about 1,275 stores and three distribution centres in 15 states with about 24,500 employees; CVS, Walgreens and others then took over about 1,000 of those stores, and the rest closed.
Takeaway: A restructuring that cuts debt but loses the suppliers' trust has not fixed the business.
Rite Aid left its first bankruptcy with less debt and fewer stores, yet still had to buy stock from vendors that now wanted strict terms. A pharmacy pays for its inventory before it sells it, so a balance sheet plan has to include how the shelves will be stocked in the months after court approval.
Case 6
Case Study 6 (FAILED): Medly, the Digital Pharmacy Failure That Began When It Could Not Buy Drugs
Medly opened its first pharmacy in Brooklyn in 2017, raised a $100 million Series B in 2020 and by the summer of 2022 operated 51 stores with more than 2,000 employees. That August a $100 million financing was withdrawn hours before the money was due to arrive. For three and a half weeks the company could not buy drugs, and sales fell by 80%.
The Business
A digital pharmacy built to offer free same-day prescription delivery, started by two second-generation pharmacy owners. In August 2021 it bought Pharmaca, a 28-store chain of integrative pharmacies founded in 2000.
The Peak/Capital
A $100 million Series B in July 2020, and a peak of 51 stores in 2022. At the filing it owed about $20 million to its first-lien bank, $81 million to a growth-capital lender, $10 million on secured notes and about $47 million of unsecured debt.
The “Bitter Pill” Details
Volume the model never reached: Medly focused on specialised prescriptions, which carry much lower margins than standard ones and are prescribed less often. Its stores never generated enough prescriptions to be profitable, and before the Pharmaca deal the digital operations lost an average of $12–14 million a month for more than a year.
An acquisition that drove away its customers: About half of Pharmaca's business was wellness products. Bringing the Medly model into those stores cost them their core customers: wealthy, middle-aged shoppers interested in health and wellness.
One lender as a single point of failure: When the lender pulled the $100 million facility on 11 August 2022, equity investors refused to fund an expected $30 million. The same month, management found operational and accounting irregularities involving the original founders. More than 20 stores closed and 52% of the workforce was separated between early August and early November.
The Financial Result
Medly filed for Chapter 11 in Delaware on 9 December 2022, listing $11.4 million in assets and $105.6 million in liabilities. Walgreens paid $19.35 million in cash for its prescription files, pharmacy inventory and intellectual property, and 22 Pharmaca locations closed.
Takeaway: In a pharmacy, inventory is the service.
Medly's app, delivery drivers and digital refills meant nothing during the weeks it could not buy medicines, because patients took their prescriptions to a pharmacy that could fill them. A pharmacy growing on borrowed money needs a funding plan that survives one lender saying no, and a stock budget protected before anything else.